SEATTLE--(BUSINESS WIRE)--MitoPharm Corporation, Inc. (Pinksheets:MTPM), announced today that it has entered into negotiations for the exclusive, worldwide licensing agreement with Hong Kong University of Science and Technology for the use and commercialization of its new, patent pending process for the extraction of "(-) Schisandrin B” and “Schisandrin B.” The terms of the agreement have not been finalized and were not disclosed.
